Knight Therapeutics Gross Profit vs. EBITDA
| KHTRF Stock | USD 3.73 0.02 0.53% |
For Knight Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Knight Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Knight Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Knight Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Knight Therapeutics over time as well as its relative position and ranking within its peers.
Knight |
Knight Therapeutics EBITDA vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Knight Therapeutics's current stock value. Our valuation model uses many indicators to compare Knight Therapeutics value to that of its competitors to determine the firm's financial worth. Knight Therapeutics is currently regarded as number one stock in gross profit category among its peers. It also is currently regarded as number one stock in ebitda category among its peers totaling about 0.50 of EBITDA per Gross Profit. The ratio of Gross Profit to EBITDA for Knight Therapeutics is roughly 1.98 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Knight Therapeutics' earnings, one of the primary drivers of an investment's value.Knight EBITDA vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Knight Therapeutics |
| = | 115.41 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Knight Therapeutics |
| = | 58.22 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Knight EBITDA Comparison
Knight Therapeutics is currently under evaluation in ebitda category among its peers.
Knight Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Knight Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Knight Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Knight Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Knight Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people.
Knight Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Knight Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Knight Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Knight Therapeutics' important profitability drivers and their relationship over time.
Use Knight Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Knight Therapeutics Pair Trading
Knight Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Knight Therapeutics position
In addition to having Knight Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Knight Pink Sheet
To fully project Knight Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Knight Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Knight Therapeutics' income statement, its balance sheet, and the statement of cash flows.